Quarterly Result18 Jul 2026, 04:50 pm
Rossari Biotech Declares Unaudited Q1 FY27 Results
AI Summary
Rossari Biotech Ltd announced its unaudited financial results for the quarter ended June 30, 2026, both standalone and consolidated. The Board of Directors approved these results following a review by the Audit Committee. The company also approved the grant of 4000 stock options under its ESOP 2019 plan and the allotment of 2500 equity shares under the same plan. Additionally, the Board approved the transfer of 100% shareholding in Rossari International Limited Company to Rossari (Singapore) Pte. Ltd. as part of an internal group restructuring. The statutory auditors have conducted a limited review of the financial results.
Key Highlights
- Unaudited financial results for Q1 FY27 declared.
- Board approved grant of 4000 stock options under ESOP 2019.
- Allotment of 2500 equity shares approved under ESOP 2019.
- Approved transfer of subsidiary shareholding for restructuring.
- Statutory auditors performed a limited review of results.
Price Impact
More from ROSSARI